PRONOVA UP LVM

Photos are meant to be representative of packaging/product you may receive if ordered. Appropriate product information will be printed on the respective labels. Dupont reserves the right to change package types at its discretion.

PRONOVA UP LVM

$104,00/ gram

Minimum 10g.
The volume ordered can be incremented by 10 grams minimum value.

Description

PRONOVA™ UP LVM is a low viscosity (20-200 mPas) sodium alginate where minimum 50% of the monomer units are mannuronate. Sold per gram, minimum order is 10 grams.

Viscosity [mPa*s] : 20-200

Appr. Mw [kDa] : 75-200

G/M Ratio : ≤ 1

Endotoxins [EU/g] : ≤ 100

Total viable count [cfu/g] : ≤ 100

Specifications

Generic Name

Sodium alginate

Storage conditions

2-8°C

Shelf life

5 years

Packaging material

Polyethylene container

ID-test

Positive

Appearance of powder

White to off-white

Appearance of solution

Clear, colorless to slightly yellowish

Apparent viscosity

20-200 mPa/s

pH

5.5-8.5

Dry matter content

≥ 85%

Mannuronic acid content

≥ 50%

Protein content

≤ 0.3%

Endotoxins

≤ 100 EU/gram

Heavy metals

≤ 40 ppm

Pb

≤ 10 ppm

Hg

≤ 1 ppm

Aerobic bacteria

≤ 100 cfu/g

Yeast and mould

≤ 100 cfu/g

Quality

NovaMatrix® produces and supplies well-characterized and documented ultrapure, bio-compatible and bio-absorbable biopolymers for use in the pharmaceutical, biotechnology and biomedical industries.

These may include, but not be limited to applications such as drug delivery, tissue engineering, cell encapsulation, and medical devices. For our ultrapure sodium alginates and sodium hyaluronate, we maintain Drug Master Files with the US FDA.

NovaMatrix® products are intended to be used in applications which require high and consistent quality provided by our manufacturing, Quality Control and Quality Assurance. NovaMatrix® manufacture PRONOVA™ sodium alginate in our facilities in Norway. We operate according to GMP guidelines and ISO standards; ISO 9001:2015 and ISO 13485:2016.

Safety & toxicology

PRONOVA™ UP sodium alginates are manufactured in accordance with GMP, ISO and ICH guidelines. Ultrapure (UP) implies that the products contain low levels of residual endotoxin. The current specification is <100 EU/g. PRONOVA™ sodium alginate products are ideal for a wide variety of pharmaceutical, biomedical, biotechnology and tissue engineering applications. The safety and toxicology profile of ultrapure PRONOVA™ sodium alginate products is described in a Drug Master File submitted to the US FDA. The table below is meant to serve as a summary over some of the studies performed and the conclusions drawn from them.